Niall C. Tebbutt

24.1k total citations · 5 hit papers
255 papers, 12.8k citations indexed

About

Niall C. Tebbutt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Niall C. Tebbutt has authored 255 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Oncology, 110 papers in Pulmonary and Respiratory Medicine and 57 papers in Surgery. Recurrent topics in Niall C. Tebbutt's work include Colorectal Cancer Treatments and Studies (144 papers), Gastric Cancer Management and Outcomes (74 papers) and Cancer Treatment and Pharmacology (45 papers). Niall C. Tebbutt is often cited by papers focused on Colorectal Cancer Treatments and Studies (144 papers), Gastric Cancer Management and Outcomes (74 papers) and Cancer Treatment and Pharmacology (45 papers). Niall C. Tebbutt collaborates with scholars based in Australia, United States and United Kingdom. Niall C. Tebbutt's co-authors include Timothy Price, John Zalcberg, Christos S. Karapetis, Derek J. Jonker, Dongsheng Tu, Malcolm J. Moore, R. J. Simes, Chris J. O’Callaghan, Christiane Langer and Jeremy Shapiro and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Niall C. Tebbutt

246 papers receiving 12.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. profile →
Cetuximab for the Treatment of Colorectal Cancer

2007 1.4k citations Derek J. Jonker, Christos S. Karapetis et al. profile →
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

2016 434 citations Qian Shi, Michel Seymour et al. profile →
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

2013 379 citations Atsushi Ohtsu, Niall C. Tebbutt et al. Journal of Clinical Oncology profile →
Targeting the ERBB family in cancer: couples therapy

2013 365 citations Niall C. Tebbutt et al. profile →

Peers

Countries citing papers authored by Niall C. Tebbutt

Since Specialization

Citations

This map shows the geographic impact of Niall C. Tebbutt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niall C. Tebbutt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niall C. Tebbutt more than expected).

Fields of papers citing papers by Niall C. Tebbutt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niall C. Tebbutt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niall C. Tebbutt. The network helps show where Niall C. Tebbutt may publish in the future.

Co-authorship network of co-authors of Niall C. Tebbutt

This figure shows the co-authorship network connecting the top 25 collaborators of Niall C. Tebbutt. A scholar is included among the top collaborators of Niall C. Tebbutt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niall C. Tebbutt. Niall C. Tebbutt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study 2024 ·Journal of Clinical Oncology ·(unknown), Guillermo Méndez, Joseph Chao, Radim Němeček, Kynan Feeney, Eric Van Cutsem, Salah‐Eddin Al‐Batran, Wasat Mansoor, N. Maisey, Roberto Pazo-Cid, Matthew Burge, David Pérez-Callejo, R. William Hipkin, (unknown), Ming Lei, Hao Tang, Satyendra Suryawanshi, Ronan J. Kelly, Niall C. Tebbutt	27
2	BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer 2024 ·Cell Death and Disease ·Laura J. Jenkins, Ian Y. Luk, Fiona Chionh, Tao Tan, (unknown), (unknown), (unknown), (unknown), Oliver M. Sieber, Dmitri Mouradov, Peter Gibbs, David S. Williams, Niall C. Tebbutt, Jayesh Desai, Frédéric Hollande, Amardeep S. Dhillon, Erinna F. Lee, Delphine Mérino, W. Douglas Fairlie, John M. Mariadason	4
3	The association of health-care contact days with physical function and survival in CCTG/AGITG CO.17 2024 ·JNCI Journal of the National Cancer Institute ·Arjun Gupta, Christopher J. O’Callaghan, Liting Zhu, Derek J. Jonker, Ralph Wong, Bruce Colwell, Malcolm J. Moore, Christos S. Karapetis, Niall C. Tebbutt, Jeremy Shapiro, Dongsheng Tu, Christopher M. Booth	7
4	Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit 2023 ·ANZ Journal of Surgery ·Charles Pilgrim, (unknown), (unknown), Jennifer Philip, (unknown), (unknown), Belinda Lee, Niall C. Tebbutt	1
5	586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial 2023 ·Annals of Oncology ·Daphne Day, (unknown), Val Gebski, John Simes, Theresa Hayes, (unknown), A. H. Strickland, Karen Briscoe, Suresh Varma, (unknown), Christopher Jackson, Lisa G. Horvath, Timothy Price, Niall C. Tebbutt, (unknown), Connie I. Diakos, (unknown), Han Chong Toh, Frederick S. Jones, Eva Segelov	1
6	SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors. 2023 ·Journal of Clinical Oncology ·Michael Jefford, Jon Emery, Andrew Martin, Richard De Abreu Lourenço, Karolina Lisy, (unknown), Dorothy King, Niall C. Tebbutt, Margaret Lee, (unknown), Adele Burgess, Julie Marker, (unknown), (unknown), (unknown), Penelope Schofield	1
7	A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study 2023 ·Clinical Cancer Research ·Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, (unknown), Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, (unknown), (unknown), David Ritchie, Rachel Koldej, Benjamin Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah‐Jane Dawson, Jayesh Desai	35
8	Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK 2021 ·Molecular Cancer Therapeutics ·(unknown), Ian Y. Luk, Laura J. Jenkins, Andrew Martin, David S. Williams, (unknown), Fiona Chionh, Michael Büchert, Katrin Marie Sjoquist, Alex Boussioutas, Sarah A. Hayes, Matthias Ernst, Andrew Weickhardt, Nick Pavlakis, Niall C. Tebbutt, John M. Mariadason	14
9	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study 2021 ·Clinical Cancer Research ·Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy Price, (unknown), Effie Skrinos, John M. Mariadason, Niall C. Tebbutt	12
10	Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer 2020 ·JNCI Cancer Spectrum ·Prunella Blinman, Andrew Martin, Michael Jefford, David Goldstein, David Boadle, (unknown), Niall C. Tebbutt, (unknown), Andrea Harkin, Eva Segelov, Andrew Haydon, Timothy Iveson, Martin R. Stockler	4
11	Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma 2020 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Vijayaragavan Muralidharan, Niall C. Tebbutt, Pok Fai Wong, Chao Fang, (unknown), Hui Gan, John Sachinidis, Kunthi Pathmaraj, Christopher Christophi, Andrew M. Scott	4
12	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer 2018 ·Clinical Cancer Research ·Amanda Townsend, Niall C. Tebbutt, Christos S. Karapetis, Pamela Cooper, Nimit Singhal, (unknown), (unknown), Rohit Joshi, Jennifer E. Hardingham, Timothy Price	6
13	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer 2014 ·Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	92
14	Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of ¹³¹I-huA33 with Concurrent Capecitabine 2014 ·Journal of Nuclear Medicine ·Rebecca Herbertson, Niall C. Tebbutt, Fook-Thean Lee, Sanjeev Gill, Bridget Chappell, (unknown), Timothy Saunder, Graeme O’Keefe, Aurora Poon, Sze Ting Lee, Roger Murphy, Wendie Hopkins, Fiona E. Scott, Andrew M. Scott	24
15	PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE 2013 ·Asia-Pacific Journal of Clinical Oncology ·Dirkje W. Sommeijer, Qian Shi, (unknown), Katrin Marie Sjoquist, (unknown), Michel Seymour, Jim Cassidy, Richard M. Goldberg, Jean‐Yves Douillard, J. Randolph Hecht, Herbert I. Hurwitz, Christophe Tournigand, Niall C. Tebbutt, Enrique Aranda, John Souglakos, Fairooz F. Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Daniel J. Sargent, John Zalcberg	2
16	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) 2012 ·Journal of Clinical Oncology ·Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi, Niall C. Tebbutt, Jin Li, Tae Won Kim, Krassimir Koynov, G. Kurteva, Tamás Pintér, Ying Cheng, Brigitte Van Eyll, Laura A. Pike, Anitra Fielding, Jane Robertson, Mark Saunders	112
17	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang, Atsushi Ohtsu, Niall C. Tebbutt, Jianming Xu, Wei Peng Yong, Bernd Langer, Paul Delmar, Stefan Scherer, Manish A. Shah	358
18	PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) 2011 ·Annals of Oncology ·Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith Mitchell, Ірина Давиденко, Élena Elez, Kelly S. Oliner, Lisa Chen, Jing Huang, Ian McCaffery, Elwyn Loh, Dominic Smethurst, Eric Van Cutsem	0
19	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study 2010 ·Journal of Clinical Oncology ·Niall C. Tebbutt, Kate Wilson, Val Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark Saunders, Martin R. Stockler, (unknown), John Zalcberg, R. J. Simes, Timothy Price	315
20	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 2010 ·Clinical Colorectal Cancer ·Timothy Price, Niall C. Tebbutt, Christos S. Karapetis, Eva Segelov, Nick Pavlakis, David Cunningham, Alberto Sobrero, Daniel G. Haller, Jeremy Shapiro	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact